Walleye Capital LLC Viking Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $1.61 Million - $2.28 Million	32,300 Added 195.76%	48,800 $3.09 Million
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $374,381 - $633,580	7,900 Added 91.86%	16,500 $874,000
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $501,119 - $2.72 Million	-28,800 Reduced 77.01%	8,600 $705,000
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $345,576 - $734,536	37,400 New	37,400 $696,000
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $78,652 - $131,387	-5,300 Reduced 38.13%	8,600 $139,000
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $112,312 - $240,886	13,900 New	13,900 $231,000

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.